Seeking Alpha

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
Hosted on MSN

Veracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCO

Veracyte, Inc. (NASDAQ:VCYT) announced that eight new studies featuring its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at the ASCO 2025 annual meeting in Chicago, ...
Business Wire

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...
Seeking Alpha

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...
Nasdaq

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Morningstar

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the ...